Jun 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Lilly's tirzepatide outperformed placebo in resolving MASH, and over 50% of patients showed fibrosis improvement after 52 weeks.

EASL Conclusion Session Emphasized Novel Clinical Data on Unique HBV-targeted TCR T Cell Therapy (SCG101) Demonstrating Enhanced Survival Rates in HBV-linked Liver Cancer.

Geron Receives FDA Approval for RYTELO™ (imetelstat), a Novel Telomerase Inhibitor, to Treat Transfusion-Dependent Anemia in Adults with Lower-Risk MDS.

Annexon Reports Preliminary Success in Phase 3 Trial of Novel C1q Inhibitor ANX005 for Guillain-Barré Syndrome.

Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.

Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.

Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).

Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.